Importance of Response to Neoadjuvant Chemotherapy in Patients Undergoing Resection of Synchronous Colorectal Liver Metastases

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2003 Feb 1

PMID 12559192

Citations 82

Authors

Peter J Allen

Nancy Kemeny

William Jarnagin

Ronald DeMatteo

Leslie Blumgart

Yuman Fong

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to compare the treatment and outcome in patients referred for staged resection of synchronous colorectal liver metastases. The records of patients who had undergone colon or rectal resection and were then referred for evaluation of clinically resectable synchronous liver metastases between January 1995 and January 2000 were reviewed. Comparisons were made between patients who did not receive neoadjuvant chemotherapy and had exploratory operations after recovery from colon resection and patients who did receive chemotherapy before liver resection. A total of 106 patients were treated during the 5-year period. Neoadjuvant chemotherapy was given to 52 of the patients; in 29 of them the disease did not progress, but in 17 patients the disease progressed while they were receiving treatment. Median follow-up was 30 months. Patient- and tumor-related variables were similar between groups. Five-year survival was statistically similar between patients who did and those who did not receive neoadjuvant chemotherapy (43% vs. 35%, P = 0.49). Patients within the neoadjuvant group whose disease did not progress while they were receiving chemotherapy experienced significantly improved survival as compared to patients who did not receive chemotherapy (85% vs. 35%, P = 0.03). In the setting of synchronous colorectal liver metastases, the response to neoadjuvant chemotherapy may be a prognostic indicator of survival and may assist in the selection of patients for conventional or experimental adjuvant therapies.

Citing Articles

The Use of Hepatic Artery Infusion Chemotherapy for Unresectable Colorectal Cancer Liver Metastases.

Vitello D, Merkow R Cancer Treat Res. 2024; 192:265-276.

PMID: 39212925 DOI: 10.1007/978-3-031-61238-1_13.

Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial.

Dong Y, Santol J, Gruenberger B, Lenauer A, Laengle F, Thaler J Cancers (Basel). 2024; 16(5).

PMID: 38473219 PMC: 10930861. DOI: 10.3390/cancers16050857.

Recurrent Colorectal Liver Metastases: Upfront Local Treatment versus Neoadjuvant Systemic Therapy Followed by Local Treatment (COLLISION RELAPSE): Study Protocol of a Phase III Prospective Randomized Controlled Trial.

Dijkstra M, Kuiper B, Schulz H, van der Lei S, Puijk R, Vos D Cardiovasc Intervent Radiol. 2023; 47(2):253-262.

PMID: 37943351 PMC: 10844349. DOI: 10.1007/s00270-023-03602-y.

The Role of Preoperative Chemotherapy in the Management of Synchronous Resectable Colorectal Liver Metastases: A Meta-Analysis.

Tepelenis K, Pappas-Gogos G, Ntellas P, Tsimogiannis K, Dadouli K, Mauri D Curr Oncol. 2023; 30(5):4499-4511.

PMID: 37232798 PMC: 10217056. DOI: 10.3390/curroncol30050340.

Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy.

Araujo R, Carvalho C, Maeda C, Milani J, Bugano D, de Moraes P World J Gastrointest Surg. 2022; 14(9):877-886.

PMID: 36185562 PMC: 9521463. DOI: 10.4240/wjgs.v14.i9.877.

References

Silen W . Hepatic resection for metastases from colorectal carcinoma is of dubious value. Arch Surg. 1989; 124(9):1021-2. DOI: 10.1001/archsurg.1989.01410090027004. View

Cady B, Stone M, McDERMOTT Jr W, Jenkins R, Bothe Jr A, Lavin P . Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg. 1992; 127(5):561-8; discussion 568-9. DOI: 10.1001/archsurg.1992.01420050085011. View

Tabira Y, Yasunaga M, Sakaguchi T, Nagamoto N, Ogi S, Kitamura N . Predicting initial recurrence pattern of esophageal cancer after neoadjuvant chemotherapy. Hepatogastroenterology. 2000; 47(35):1315-8. View

Lyass S, Zamir G, Matot I, Goitein D, Eid A, Jurim O . Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol. 2001; 78(1):17-21. DOI: 10.1002/jso.1117. View

Chollet P, Amat S, Cure H, De Latour M, Le Bouedec G, Mouret-Reynier M . Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002; 86(7):1041-6. PMC: 2364175. DOI: 10.1038/sj.bjc.6600210. View

Bathe O, Franceschi D, Livingstone A, Moffat F, Tian E, Ardalan B . Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am. 1999; 5(1):34-40. View

Gayowski T, Iwatsuki S, Madariaga J, Selby R, Todo S, Irish W . Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994; 116(4):703-10; discussion 710-1. PMC: 2967179. View

Iwatsuki S, Dvorchik I, Madariaga J, Marsh J, DODSON F, Bonham A . Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999; 189(3):291-9. PMC: 2967754. DOI: 10.1016/s1072-7515(99)00089-7. View

Doko M, Zovak M, Ledinsky M, Mijic A, Peric M, Kopljar M . Safety of simultaneous resections of colorectal cancer and liver metastases. Coll Antropol. 2001; 24(2):381-90. View

10.

Schlag P, Hohenberger P, Herfarth C . Resection of liver metastases in colorectal cancer--competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol. 1990; 16(4):360-5. View

11.

Shankar A, Leonard P, Renaut A, Lederman J, Lees W, Gillams A . Neo-adjuvant therapy improves resectability rates for colorectal liver metastases. Ann R Coll Surg Engl. 2001; 83(2):85-8. PMC: 2503337. View

12.

Sugawara Y, Yamamoto J, Yamasaki S, Shimada K, Kosuge T, Makuuchi M . Estimating the prognosis of hepatic resection in patients with metastatic liver tumors from colorectal cancer with special concern for the timing of hepatectomy. Surgery. 2001; 129(4):408-13. DOI: 10.1067/msy.2001.112001. View

13.

Eilber F, Rosen G, Eckardt J, Forscher C, Nelson S, Selch M . Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001; 19(13):3203-9. DOI: 10.1200/JCO.2001.19.13.3203. View

14.

Banerjee D, Gorlick R, Liefshitz A, Danenberg K, Danenberg P, Danenberg P . Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res. 2000; 60(9):2365-7. View

15.

Fujita S, Akasu T, Moriya Y . Resection of synchronous liver metastases from colorectal cancer. Jpn J Clin Oncol. 2000; 30(1):7-11. DOI: 10.1093/jjco/hyd002. View

16.

Jatzko G, Wette V, Muller M, Lisborg P, Klimpfinger M, Denk H . Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital. Int J Colorectal Dis. 1991; 6(2):111-4. DOI: 10.1007/BF00300206. View

17.

Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D . Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996; 224(4):509-20; discussion 520-2. PMC: 1235414. DOI: 10.1097/00000658-199610000-00009. View

18.

Scheele J, Stang R, Altendorf-Hofmann A, Paul M . Resection of colorectal liver metastases. World J Surg. 1995; 19(1):59-71. DOI: 10.1007/BF00316981. View

19.

Fong Y, Fortner J, Sun R, Brennan M, Blumgart L . Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230(3):309-18; discussion 318-21. PMC: 1420876. DOI: 10.1097/00000658-199909000-00004. View